Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer

Journal Article · Wed Jul 19 04:00:00 EDT 2023 · Nuclear Medicine and Biology

DOI:https://doi.org/10.1016/j.nucmedbio.2023.108368· OSTI ID:1993381

Hoffman, Sabrina L. V. ^[1]; Mixdorf, J. C. ^[2]; Kwon, O. ^[2]; Johnson, T. R. ^[2]; Makvandi, M. ^[3]; Lee, H. ^[3]; Aluicio-Sarduy, E. ^[2]; Barnhart, T. E. ^[2]; Jeffery, J. J. ^[4]; Patankar, M. S. ^[2]; Engle, J. W. ^[2]; Bednarz, B. P. ^[2]; Ellison, P. A. ^[2]

---

1. Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health; University of Wisconsin School of Medicine and Public Health Department of Medical Physics
2. Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health
3. Univ. of Pennsylvania, Philadelphia, PA (United States). Perelman School of Medicine
4. Univ. of Wisconsin, Madison, WI (United States). Carbone Cancer Center

Advanced ovarian cancer currently has few therapeutic options. Poly(ADP-ribose) polymerase (PARP) inhibitors bind to nuclear PARP and trap the protein-inhibitor complex to DNA. This work investigates a theranostic PARP inhibitor for targeted radiopharmaceutical therapy of ovarian cancer in vitro and PET imaging of healthy mice in vivo. Methods: [⁷⁷Br]RD1 was synthesized and assessed for pharmacokinetics and cytotoxicity in human and murine ovarian cancer cell lines. [⁷⁶Br]RD1 biodistribution and organ uptake in healthy mice were quantified through longitudinal PET/CT imaging and ex vivo radioactivity measurements. Organ-level dosimetry following [^76/77Br]RD1 administration was calculated using RAPID, an in-house platform for absorbed dose in mice, and OLINDA for equivalent and effective dose in human. Results: The maximum specific binding (B_max), equilibrium dissociation constant (K_d), and nonspecific binding slope (NS) were calculated for each cell line. These values were used to calculate the cell specific activity uptake for cell viability studies. The half maximal effective concentration (EC₅₀) was measured as 0.17 (95 % CI: 0.13–0.24) nM and 0.46 (0.13–0.24) nM for PARP(+) and PARP(–) expressing cell lines, respectively. The EC₅₀ was 0.27 (0.21–0.36) nM and 0.30 (0.22–0.41) nM for BRCA1(–) and BRCA1(+) expressing cell lines, respectively. When measuring the EC₅₀ as a function of cellular activity uptake and nuclear dose, the EC₅₀ ranges from 0.020 to 0.039 Bq/cell and 3.3–9.2 Gy, respectively. Excretion through the hepatobiliary and renal pathways were observed in mice, with liver uptake of 2.3 ± 0.4 %ID/g after 48 h, contributing to estimated absorbed dose values in mice of 19.3 ± 0.3 mGy/MBq and 290 ± 10 mGy/MBq for [⁷⁷Br]RD1 and [⁷⁶Br]RD1, respectively. Conclusion: [⁷⁷Br]RD1 cytotoxicity was dependent on PARP expression and independent of BRCA1 status. Finally, the in vitro results suggest that [⁷⁷Br]RD1 cytotoxicity is driven by the targeted Meitner-Auger electron (MAe) radiotherapeutic effect of the agent. Further studies investigating the theranostic potential, organ dose, and tumor uptake of [^76/77Br]RD1 are warranted.

• Research Organization: Univ. of Wisconsin, Madison, WI (United States)
• Sponsoring Organization: USDOE Office of Science (SC), Office of Isotope R&D and Production (IRP); National Cancer Institute (NCI)
• Contributing Organization: University of Wisconsin Carbone Cancer Center (UWCCC) Biostatistics Shared Resource; UWCCC Small Animal Imaging & Radiotherapy Facility
• Grant/Contract Number: SC0020960
• OSTI ID: 1993381
• Journal Information: Nuclear Medicine and Biology, Journal Name: Nuclear Medicine and Biology Vol. 122-123; ISSN 0969-8051
• Publisher: Elsevier
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
Bromine-76
Bromine-77
Meitner-Auger radionuclide therapy
PARP-1 inhibitor
ovarian cancer therapy
positron emission tomography
theranostic